REPORT FROM THE AHA/ASA INTERNATIONAL STROKE CONFERENCE – A retrospective analysis of data from the Vitamin Intervention for Stroke Prevention (VISP) trial has examined the impact of patient adherence on clinical outcomes (Ovbiagele et al. Abstract P466).
Read More
Neurology
Inadequate ASA response common in secondary stroke prevention
March 24, 2009REPORT FROM THE AHA/ASA INTERNATIONAL STROKE CONFERENCE – Patients who do not respond to low-dose acetylsalicylic acid (ASA) for secondary stroke prevention are unlikely to respond to a higher dose, according to researchers at the University of Buffalo, NY (Gengo et al. Abstract 85).
Read More
Switching MS therapies effective after treatment failure
March 10, 2009
Leave a reply
For multiple sclerosis patients who fail to respond to a first-line disease-modifying treatment (DMT), switching to another DMT is a generally effective strategy, according to an analysis by U.S. and Italian researchers (Gajofatto et al. Mult Scler 2009;15:50-58).
Head injury not associated with MS
March 10, 2009A prospective cohort study in Denmark has found that head injury is not associated with an increased risk of developing multiple sclerosis (Pfleger et al. Mult Scler 2008; epublished November 21, 2008).
Galantamine in PD with and without dementia
March 10, 2009Cognitive dysfunction (primarily executive, visuospatial and memory function) can occur in Parkinson disease as a result of cortical and subcortical changes, with an estimated 20-40% of patients eventually developing dementia (Bosboom et al. J Neural Transm 2004;111:1303-1315). The pathophysiology of PD dementia has not been fully elucidated but may be due, in part, to cholinergic deficiency in the cerebral cortex, cortical Lewy bodies and other Alzheimer disease-like pathology.